BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.7921
-0.0979 (-11.00%)
At close: Aug 18, 2026, 4:00 PM EDT
0.8105
+0.0184 (2.32%)
After-hours: Aug 18, 2026, 7:48 PM EDT

BioXcel Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
0.740.642.271.380.38-
Revenue Growth
-14.52%-71.67%64.20%268.00%--
Cost of Revenue
0.350.162.141.260.02-
Gross Profit
0.390.480.120.120.36-
Selling, General & Admin
23.5720.4934.4983.4168.7654.59
Research & Development
21.5630.2530.4484.3391.2452.34
Operating Expenses
45.1350.7564.93167.74160106.94
Operating Income
-44.73-50.27-64.8-167.62-159.65-106.94
Interest Expense
-17.22-16.98-15.13-13.31-8.21-0.04
Interest & Investment Income
0.91.072.65.652.530.04
Other Non Operating Income (Expenses)
-9.61-3.5220.170.39-0.43-
EBT Excluding Unusual Items
-70.67-69.7-57.16-174.89-165.76-106.93
Merger & Restructuring Charges
-0.19-0.19-2.44-4.16--
Pretax Income
-70.86-69.9-59.6-179.05-165.76-106.93
Net Income
-70.86-69.9-59.6-179.05-165.76-106.93
Net Income to Common
-70.86-69.9-59.6-179.05-165.76-106.93
Net Income Growth
------
Shares Outstanding (Basic)
23123222
Shares Outstanding (Diluted)
23123222
Shares Change
389.70%381.58%39.21%4.00%6.23%21.63%
EPS (Basic)
-3.15-5.73-23.51-98.33-94.67-64.87
EPS (Diluted)
-3.15-5.73-23.51-98.33-94.67-64.87
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-50.9-57.62-72.03-155.03-135.48-82.6
Free Cash Flow Per Share
-2.26-4.72-28.41-85.13-77.38-50.11
Gross Margin
53.10%74.45%5.43%8.70%94.67%-
Operating Margin
-6028.57%-7829.75%-2859.84%-12146.30%-42572.00%-
Profit Margin
-9549.86%-10887.38%-2630.14%-12974.85%-44201.87%-
Free Cash Flow Margin
-6860.38%-8974.30%-3178.60%-11233.77%-36128.00%-
EBITDA
-44.51-49.97-64.5-167.3-159.32-106.64
D&A For EBITDA
0.230.30.310.320.330.3
EBIT
-44.73-50.27-64.8-167.62-159.65-106.94
SEC Filings: 10-K · 10-Q